Indivior files patent lawsuits over addiction treatment

Pharmaceutical company Indivior plc said its US subsidiary Indivior Inc. has filed patent lawsuits against Dr. Reddy’s, Actavis, Par, Alvogen and Teva for alleged infringement of a US patent relating to their respective proposed generic versions of Indivior’s Suboxone Film opioid addiction treatment that generates most of its revenues

“These lawsuits allege that the aforementioned companies infringe the ‘305 patent, which was issued on April 3rd and has been submitted for listing in the FDA’s Orange Book,” said Indivior.

“The ‘305 patent claims film compositions having a substantially uniform distribution of active drug.

“Indivior has been involved in patent infringement litigation involving other, earlier issued patents covering Suboxone Film with these same companies relating to their proposed generic products.”

Indivior CEO Shaun Thaxter said: “The ‘305 patent, along with the other new Orange Book patents that we secured (the ‘454 and ‘221 patents), demonstrates our commitment to innovate and generate new intellectual property for the Suboxone Film.

“As a follow-on to our ‘514 patent, we believe this new patent is strong and we are asserting it to protect our intellectual property rights.”